Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
Hematology
How would you approach a young, fit patient with suspected CNS involvement with high circulating blasts?
What induction and IT regimens do you use for patients with confirmed AML with CNS involvement?
Related Questions
For patients with newly diagnosed AML who are induction chemotherapy eligible, do you dose reduce cytarabine for any mild elevation in AST/ALT?
How would you treat a patient with newly diagnosed low-risk acute promyelocytic leukemia who has a baseline wide QTc interval, such that arsenic trioxide cannot be used?
If a bone marrow biopsy reveals mast cell leukemia, would you consider treating with avapritinib?
What are the treatment options for relapsed T-ALL in a patient who was nonadherent with AALL and hyper-CVAD regimens?
What is your approach to management of relapsed/refractory T-cell prolymphocytic leukemia (T-PLL)?
Does treating CLL reduce the risk of non-melanoma skin cancers?
How do you manage persistent cytopenias after FCR chemotherapy for treatment of CLL?
What would be an appropriate frontline AML regimen for transplant ineligible patients with chronic kidney disease (creatinine 2.5 or higher)?
What are your top takeaways in Hematologic Malignancies from ASH 2024?
In patients with post-PV myelofibrosis who are ineligible for allogeneic stem cell transplant, how do you approach symptomatic splenomegaly refractory to splenic radiation and ruxolitinib?